Key result
In children with acute lymphoblastic leukemia receiving anthracycline therapy, cardiac abnormalities were detected across all chemotherapy phases, most commonly tachycardia (42.5%) and increased left ventricular mass index (37.5%).
Why the study?
Does anthracycline chemotherapy cause cardiotoxicity in childhood acute lymphoblastic leukemia patients?
Population
Childhood acute lymphoblastic leukemia patients hospitalized at DR Sardjito hospital between April and June…
Design
Cross-sectional
Authors
Loading...
Cardiac surveillance warranted throughout anthracycline therapy in childhood ALL; leaves open causality and long-term prognostic value.
Cross-Sectional (n=40)
No
Does anthracycline chemotherapy cause cardiotoxicity in childhood acute lymphoblastic leukemia patients?
Anthracycline chemotherapy in childhood ALL is associated with cardiotoxicity that can occur at any stage of treatment.
WA’U et al. (2017) conducted a cross-sectional in Acute Lymphoblastic Leukemia (ALL) (n=40). Anthracycline was evaluated on Cardiac abnormalities (echocardiography and ECG findings). In children with acute lymphoblastic leukemia receiving anthracycline therapy, cardiac abnormalities were detected across all chemotherapy phases, most commonly tachycardia (42.5%) and increased left ventricular mass index (37.5%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: